277 related articles for article (PubMed ID: 29276983)
1. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
2. A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study.
Ferrari D; Bagaglio S; Raso M; Galli L; Premaschi S; Messina E; Morsica G; Locatelli M; Uberti-Foppa C; Hasson H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jul; 1120():1-7. PubMed ID: 31055190
[TBL] [Abstract][Full Text] [Related]
3. A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma.
Ariaudo A; Favata F; De Nicolò A; Simiele M; Paglietti L; Boglione L; Cardellino CS; Carcieri C; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2016 Jun; 125():369-75. PubMed ID: 27131146
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS.
Shi X; Zhu D; Lou J; Zhu B; Hu AR; Gan D
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():353-7. PubMed ID: 26363369
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
Biomed Chromatogr; 2018 Jun; 32(6):e4186. PubMed ID: 29314090
[TBL] [Abstract][Full Text] [Related]
6. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study.
Rezk MR; Basalious EB; Karim IA
J Pharm Biomed Anal; 2015 Oct; 114():97-104. PubMed ID: 26037157
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Pan C; Chen Y; Chen W; Zhou G; Jin L; Zheng Y; Lin W; Pan Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():255-259. PubMed ID: 26684720
[TBL] [Abstract][Full Text] [Related]
8. Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS.
van Seyen M; de Graaff Teulen MJA; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():15-24. PubMed ID: 30776611
[TBL] [Abstract][Full Text] [Related]
9. Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies.
Rezk MR; Bendas ER; Basalious EB; Karim IA
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():63-70. PubMed ID: 27322631
[TBL] [Abstract][Full Text] [Related]
10. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Youssef AA; Magdy N; Hussein LA; El-Kosasy AM
J Chromatogr Sci; 2019 Aug; 57(7):636-643. PubMed ID: 31063182
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study.
Rezk MR; Bendas ER; Basalious EB; Karim IA
J Pharm Biomed Anal; 2016 Sep; 128():61-66. PubMed ID: 27232152
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Parisi SG; Loregian A; Andreis S; Nannetti G; Cavinato S; Basso M; Scaggiante R; Dal Bello F; Messa L; Cattelan AM; Palù G
Int J Infect Dis; 2016 Aug; 49():151-3. PubMed ID: 27378577
[TBL] [Abstract][Full Text] [Related]
13. Novel and sensitive UPLC-MS/MS method for quantification of sofosbuvir in human plasma: application to a bioequivalence study.
Rezk MR; Basalious EB; Amin ME
Biomed Chromatogr; 2016 Sep; 30(9):1354-62. PubMed ID: 26821881
[TBL] [Abstract][Full Text] [Related]
14. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Atia NN; El-Shaboury SR; El-Gizawy SM; Abo-Zeid MN
J Pharm Biomed Anal; 2018 Sep; 158():88-93. PubMed ID: 29864695
[TBL] [Abstract][Full Text] [Related]
16. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G
J Pharm Biomed Anal; 2013 May; 78-79():217-23. PubMed ID: 23501442
[TBL] [Abstract][Full Text] [Related]
17. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a new HPLC-DAD method for quantification of sofosbuvir in human serum and its comparison with LC-MS/MS technique: Application to a bioequivalence study.
Miraghaei S; Mohammadi B; Babaei A; Keshavarz S; Bahrami G
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():118-122. PubMed ID: 28858753
[TBL] [Abstract][Full Text] [Related]
19. Development a validated highly sensitive LC-MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study.
Abdallah OM; Abdel-Megied AM; Gouda AS
J Pharm Biomed Anal; 2017 Sep; 143():305-310. PubMed ID: 28645021
[TBL] [Abstract][Full Text] [Related]
20. UPLC-MS/MS method for determination of sofosbuvir in human plasma.
Gandhi BM; Rao AL; Rao JV
Ann Pharm Fr; 2017 Jul; 75(4):257-266. PubMed ID: 28495020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
